Impact of prior chemotherapy with two different fluoropyrimidines on the efficacy of capecitabine plus irinotecan or FOLFIRI with or without bevacizumab in metastatic colorectal cancer: a post hoc analysis of the AXEPT study

• Satoru Iwasa,
• Zi‐Xian Wang,
• Kei Muro,
• Satoshi Morita,
• Young Suk Park,
• Dongsheng Zhang,
• Yasuhide Yamada,
• Junichi Sakamoto,
• Tae Won Kim

Affiliations

Satoru Iwasa

Department of Gastrointestinal Medical Oncology National Cancer Center Hospital Tokyo Japan

Zi‐Xian Wang

Department of Medical Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong P. R. China

Kei Muro

Department of Clinical Oncology Aichi Cancer Center Hospital Nagoya Japan

Satoshi Morita

Department of Biomedical Statistics and Bioinformatics Graduate School of Medicine Kyoto University Kyoto Japan

Young Suk Park

Division of Hematology‐Oncology Department of Medicine Samsung Medical Center Sungkyunkwan University School of Medicine Seoul Korea

Dongsheng Zhang

Department of Medical Oncology Sun Yat‐sen University Cancer Center Guangzhou Guangdong P. R. China

Yasuhide Yamada

Comprehensive Cancer Center National Center for Global Health and Medicine Tokyo Japan

Junichi Sakamoto

Tokai Central Hospital Kakamigahara Japan

Tae Won Kim

Department of Oncology Asan Medical Center University of Ulsan College of Medicine Seoul Korea